Aspen Neuroscience to Showcase Innovative Parkinson's Treatment at ISSCR 2025

Aspen Neuroscience at ISSCR 2025

Aspen Neuroscience, Inc. is set to participate in the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, an event that will take place in Hong Kong from June 11 to June 14, 2025. This year’s theme, "Illuminating the Future," underscores the importance of stem cell research and its potential impact on regenerative medicine.

At this setting, Andrés Bratt-Leal, PhD, the co-founder and Senior Vice President of Research and Development at Aspen, will present his work on the safety, tolerability, and efficacy of transplanted autologous iPSC-derived dopaminergic precursors in patients suffering from moderate to advanced Parkinson's disease. Dr. Bratt-Leal's insights will focus on the early data from the ASPIRO Study, a pivotal Phase 1/2a clinical trial evaluating the company’s innovative cell therapy, referred to as ANPD001.

The primary objective of the ASPIRO study is to ensure the safety and tolerability of the procedure, which involves the intracranial implantation of dopaminergic neuronal precursor cells (DANPCs) derived from autologous induced pluripotent stem cells (iPSCs). As neurological complications often accompany the progression of Parkinson's disease, the development of effective treatments is crucial for those impacted by this debilitating condition.

Recent findings reported by Dr. Bratt-Leal indicate that the precision intracranial delivery of DANPCs is both safe and well-tolerated by the initial cohort of patients. Early indications suggest that participants are showing positive changes when measured against several clinician-reported and patient-reported outcomes. Notably, one of the significant advantages of this autologous iPSC-derived therapy is its ability to eliminate the need for immunosuppressive medications, which are often required in conventional stem cell therapies.

About Aspen Neuroscience

Founded and headquartered in San Diego, Aspen Neuroscience is a clinical development-stage company focused on addressing high unmet medical needs through autologous regenerative medicine. Acknowledging the limitations of current Parkinson's treatments, the company employs a patient-derived iPSC platform to create customized therapies aimed specifically at neurological conditions.

Aspen’s approach combines advanced methodologies from cell biology with cutting-edge machine learning and genomics to create new regenerative therapies. Their best-in-class platform includes in-house bioinformatics and manufacturing capabilities, designed to optimize pluripotent-derived cell therapies effectively.

For updates and additional information regarding their breakthrough research and development, interested parties are invited to check Aspen's official website or reach out via email.

The ASPIRO study receives funding from the California Institute for Regenerative Medicine (CIRM), reflecting a strong commitment to advancing the field of regenerative medicine and stem cell therapy.

Stay tuned for more updates from the ISSCR 2025, as innovative treatments and research unfold, potentially changing the landscape for patients with Parkinson's disease and other neurological disorders.